InvestorsHub Logo
Followers 61
Posts 7519
Boards Moderated 2
Alias Born 02/10/2010

Re: fung_derf post# 43694

Wednesday, 03/06/2024 3:56:12 PM

Wednesday, March 06, 2024 3:56:12 PM

Post# of 43716
IMO you're on the right track with your bit about the history of drawn-out finance deals. But I would assert that in addition the long, long, long delays in getting their Phase III rolling soiled the management's reputation. That initial CRO flaking out on them really put a crimp on their getting the trial ramped up - that cost them a couple of years, a lot of both financial and social capital.

Then the study post-treatment period ended up being longer than was stated it would be. Then it took forever to get the data locked, analyzed, and the initial whole-cohort population (as a whole) didn't appear to meet the primary endpoints for success. Then it took them what seemed like years to get the biomarkers for the target subpopulation and the patient assessment criteria in place.

Recent financing of operations has at least been generally transparent. In the past, that definitely could not be said to be true.

They do appear to have at least most of their ducks in a row and marching steadily forward now. That's promising.

“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVM News